化疗联合DC-CIK治疗老年晚期非小细胞肺癌的疗效评价  

Curative Effect of Chemotherapy Combined with DC-CIK in Treatment of Elderly Patients with Advanced Nonsmall Cell lung Cancer

作　　者：马楠[1] 马东初[2] 丁震宇[1] 朴瑛[1] 郭放[1] 刘兆喆[1] 韩雅玲[3] 谢晓冬[1] 

机构地区：[1]沈阳军区总医院全军肿瘤诊治中心肿瘤科,沈阳100840 [2]沈阳军区总医院全军肿瘤诊治中心医学实验科,沈阳100840 [3]沈阳军区总医院全军心血管病研究所,沈阳100840

出　　处：《解放军医药杂志》2015年第1期37-40,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：科技部十二五重大新药创制平台子课题(2012ZX09303016-002);辽宁省科技攻关计划课题(2012225019)

摘　　要：目的探讨化疗联合树突细胞诱导的细胞因子激活的杀伤细胞(DC-CIK)治疗晚期非小细胞肺癌的疗效。方法收集2010年1月—2012年1月收治的非小细胞肺癌62例设为DC-CIK组,应用化疗联合DC-CIK治疗。选择发病时间、年龄相近,性别、病理及分期(大多为临床分期)相同的肺癌62例设为对照组,应用相同化疗。比较两组2年内中位生存时间及总生存率。结果 DC-CIK组和对照组中位生存期分别为16、13个月。DC-CIK组生存率明显高于对照组(P<0.05)。结论老年非小细胞肺癌患者应用化疗联合DC-CIK治疗,能显著提高2年内的中位生存时间和总生存率。Objective To explore the curative effect of chemotherapy combined with DC-CIK（ dendritic cell-cytokine-induced killer） cells in treatment of advanced non-small cell lung cancer. Methods A total of 62 patients with non-small cell lung cancer admitted during January 2010 and January 2012 were chosen as DC-CIK group,and received chemotherapy combined with DC-CIK therapy. Another group of 62 patients with lung cancer with similar onset time and age,and same gender,pathologic stage and clinical stage were selected as control group and treated with the same chemotherapy. The middle survival rates and overall survival rate within 2 years in the two groups were compared. Results The middle survival rate of DC-CIK group and control group were 16 and 13 months respectively. The survival rate of DCCIK group was significantly higher than that of control group（ P〈0. 05）. Conclusion Chemotherapy combined with DC-CIK cells in treatment of middle and elderly patients with advanced non-small cell lung cancer may significantly increase the middle survival time and overall survival rate within 2 years.

关 键 词：癌 非小细胞肺 细胞因子诱导杀伤细胞 抗肿瘤联合化疗方案 维持化疗 治疗结果 

分 类 号：R730.26[医药卫生—肿瘤]